Pancreatic Cancer Research

ResearcherHoward Hughes Medical InstituteActive in the last 2 years

Amanda L. Blackford

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6519-4833; OpenAlex author ID A5012591920. Sources: OpenAlex.

Their work

Papers
32 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
112
Papers, trials and grants by year

2012: 3 papers · 2013: 2 papers · 2014: none · 2015: 4 papers · 2016: 3 papers · 2017: 2 papers · 2018: 2 papers · 2019: 2 papers · 2020: 3 papers · 2021: 2 papers · 2022: 1 paper · 2023: none · 2024: 3 papers · 2025: 4 papers · 2026: 1 paper

Papers 32

  1. Association of obstructive sleep apnea with pancreatic cancer in high-risk patients under surveillance in CAPS and PCYST cohorts. Co-author DOI 10.1016/j.pan.2026.10.013↗
  2. Concerns Regarding the Utility of High-Risk Pancreatic Cancer Surveillance-Reply. Co-author DOI 10.1001/jamaoncol.2024.5522↗
  3. Mild Dilatation of the Main Pancreatic Duct Is a Risk Factor for Progression to Pancreatic Cancer in High-Risk Individuals. Co-author DOI 10.1016/j.gastha.2025.100802↗
  4. The Mutational Status of Driver Genes in Patients With Resected Pancreatic Ductal Adenocarcinoma Is Associated With Pathological Characteristics and Overall Su… Co-author DOI 10.1097/sla.0000000000006794↗
  5. Personalizing CA125 Levels Using Tumor Marker Variants: A Case-Control Analysis of Diagnostic Performance for Pancreatic Cancer. Co-author DOI 10.1158/1055-9965.epi-25-1050↗
  6. Pancreatic Cancer Surveillance and Survival of High-Risk Individuals. Co-author DOI 10.1001/jamaoncol.2024.1930↗
  7. Using Tumor Marker Gene Variants to Improve the Diagnostic Accuracy of DUPAN-2 and Carbohydrate Antigen 19-9 for Pancreatic Cancer. Co-author DOI 10.1200/jco.23.01573↗
  8. Using a CA19-9 Tumor Marker Gene Test to Assess Outcome After Pancreatic Cancer Surgery. Co-author DOI 10.1245/s10434-024-14942-5↗
  9. Serum Carboxypeptidase Activity and Genotype-Stratified CA19-9 to Detect Early-Stage Pancreatic Cancer. Co-author DOI 10.1016/j.cgh.2021.10.008↗
  10. A risk prediction tool for individuals with a family history of breast, ovarian, or pancreatic cancer: BRCAPANCPRO. Co-author DOI 10.1038/s41416-021-01580-x↗
  11. Smoking Modifies Pancreatic Cancer Risk Loci on 2q21.3. Co-author DOI 10.1158/0008-5472.can-20-3267↗
  12. Surgical Outcomes After Pancreatic Resection of Screening-Detected Lesions in Individuals at High Risk for Developing Pancreatic Cancer. Co-author DOI 10.1007/s11605-019-04230-z↗
  13. Recent Trends in the Incidence and Survival of Stage 1A Pancreatic Cancer: A Surveillance, Epidemiology, and End Results Analysis. Co-author DOI 10.1093/jnci/djaa004↗
  14. Genome-Wide Gene-Diabetes and Gene-Obesity Interaction Scan in 8,255 Cases and 11,900 Controls from PanScan and PanC4 Consortia. Co-author DOI 10.1158/1055-9965.epi-20-0275↗
  15. The Significance of Ascites in Patients With Pancreatic Ductal Adenocarcinoma: A Case-Control Study. Co-author DOI 10.1097/mpa.0000000000001262↗
  16. Analysis of Heritability and Genetic Architecture of Pancreatic Cancer: A PanC4 Study. Co-author DOI 10.1158/1055-9965.epi-18-1235↗
  17. Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. Co-author DOI 10.1038/s41467-018-02942-5↗
  18. Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance. Co-author DOI 10.1053/j.gastro.2018.05.035↗
  19. Circulating Tumor Cells Expressing Markers of Tumor-Initiating Cells Predict Poor Survival and Cancer Recurrence in Patients with Pancreatic Ductal Adenocarcin… First author DOI 10.1158/1078-0432.ccr-16-1467↗
  20. Duodenal Involvement is an Independent Prognostic Factor for Patients with Surgically Resected Pancreatic Ductal Adenocarcinoma. First author DOI 10.1245/s10434-017-5864-9↗
  21. Longer Course of Induction Chemotherapy Followed by Chemoradiation Favors Better Survival Outcomes for Patients With Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/coc.0000000000000022↗
  22. Circulating Tumor Cell Phenotype Predicts Recurrence and Survival in Pancreatic Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000001600↗
  23. Obstructive Sleep Apnea and Pathological Characteristics of Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1371/journal.pone.0164195↗
  24. Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. Co-author DOI 10.1038/ng.3341↗
  25. Time to progression of pancreatic ductal adenocarcinoma from low-to-high tumour stages. First author DOI 10.1136/gutjnl-2014-308653↗
  26. Very Long-term Survival Following Resection for Pancreatic Cancer Is Not Explained by Commonly Mutated Genes: Results of Whole-Exome Sequencing Analysis. Co-author DOI 10.1158/1078-0432.ccr-14-2600↗
  27. The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution Experience. Co-author DOI 10.1245/s10434-014-4274-5↗
  28. Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer. Co-author DOI 10.1016/j.ijrobp.2013.03.032↗
  29. Correlation of Smad4 status with outcomes in patients receiving erlotinib combined with adjuvant chemoradiation and chemotherapy after resection for pancreatic… Co-author DOI 10.1016/j.ijrobp.2013.06.2039↗
  30. A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma. Co-author DOI 10.1007/s00280-011-1704-y↗
  31. Genetically defined subsets of human pancreatic cancer show unique in vitro chemosensitivity. Co-author DOI 10.1158/1078-0432.ccr-12-0827↗
  32. Development of a novel preclinical pancreatic cancer research model: bioluminescence image-guided focal irradiation and tumor monitoring of orthotopic xenograf… Co-author DOI 10.1593/tlo.11316↗

Closest collaborators

The 25 strongest of 112 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michael Goggins · 18 shared papers, 2015–2026 · strength 2.62
  2. Marcia Irene Canto · 10 shared papers, 2018–2026 · strength 1.95
  3. Jin Peng He · 10 shared papers, 2017–2025 · strength 1.59
  4. Ralph H. Hruban · 15 shared papers, 2012–2025 · strength 1.37
  5. Richard Andrew Burkhart · 6 shared papers, 2020–2025 · strength 1.00
  6. Takeichi Yoshida · 4 shared papers, 2022–2025 · strength 0.75
  7. Christopher Lee Wolfgang · 13 shared papers, 2013–2020 · strength 0.73
  8. Alison P. Klein · 6 shared papers, 2018–2024 · strength 0.64
  9. Anne Marie Lennon · 5 shared papers, 2018–2024 · strength 0.63
  10. Helena Saba · 3 shared papers, 2024–2025 · strength 0.62
  11. Elizabeth Abou Diwan · 3 shared papers, 2024–2025 · strength 0.62
  12. Eun Ji Shin · 4 shared papers, 2018–2026 · strength 0.57
  13. Elham Afghani · 2 shared papers, 2025–2026 · strength 0.50
  14. Marco Dal Molin · 5 shared papers, 2015–2025 · strength 0.44
  15. James R. Eshleman · 3 shared papers, 2012–2024 · strength 0.40
  16. Yohei Ando · 2 shared papers, 2024 · strength 0.37
  17. Matthew John Weiss · 6 shared papers, 2015–2020 · strength 0.37
  18. Elliot K. Fishman · 4 shared papers, 2016–2024 · strength 0.36
  19. Ihab R. Kamel · 3 shared papers, 2018–2024 · strength 0.32
  20. Joseph M. Herman · 7 shared papers, 2012–2019 · strength 0.30
  21. Daniel A. Laheru · 7 shared papers, 2012–2019 · strength 0.30
  22. Sapna Syngal · 2 shared papers, 2021–2024 · strength 0.28
  23. Hassan Sinan · 1 shared paper, 2026 · strength 0.26
  24. Richard David Schulick · 5 shared papers, 2013–2020 · strength 0.25
  25. Masataka Hayashi · 1 shared paper, 2025 · strength 0.25

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.